

ANTIBIOTICS

ANTIMICROBIAL SUSCEPTIBILITY
PROFILE for 2022
ORGANISMS Isolated in 2021

	Number tested	Penicillin	Ampicillin	Amoxicillin/Clav	Ampicillin/Sulbac	Oxacillin	Cefazolin (1)	Cefoxitin (2)	Cefuroxime (2)	Ceftazidime (3)	# Ceftriaxone (3)	Cefepime	Clindamycin ****	Tetracycline	Tobramycin	Gentamicin	Ertapenem	Meropenem	Piperacilin/Tazo	Vancomycin	Daptomycin	Linezolid	Levofloxacin	Ciprofloxacin	Trimeth/Sulfa	Nitrofurantoin(UTI only)	Rifampin*
Escherichia coli **	999	55	84	64		91	92	93	95	93	95			93	94	100	100	99					87	92	79	98	
Klebsiella pneumoniae**	160		98	88		98	96	93	98	98	98			96	99	100	99	99					94	94	88	39	
Klebsiella oxytoca	46		96	63		87	100	96	100	98	100			94	98	100	100	98					98	98	91	84	
Enterobacter cloacae	62								76	76	98			100	100	100	98	74					100	100	98	41	
Proteus mirabilis	64	81	100	91		94	92	95	95	95	95			97	92	100	100	100					70	67	78		
Pseudomonas aeruginosa***	87								97		98			100	94		98	100					84	87			
Staphylococcus aureus MSSA	252				100								86	96		99				100	100	100	94	94	98	100	100
Staphylococcus aureus MRSA	130												81	91		94				100	100	100	32	32	94	100	100
MRSA RATE 34%																											
Staphylococcus epidermidis	83				43								66		94					99	100	100	74	74	70	100	99
Enterococcus faecalis	169	100																		99	100	100	92	91		100	
Streptococcus pneumoniae	28	100								93		82	82							100			100		75		

Blank indicates insufficient data, inappropriate organism/drug combination, or susceptibility less than 10%.

Ceftriaxone for S. pneumoniae percent sensitive using meningitis breakpoint is 74% , using non-meningitis breakpoint is 93%.

*Rifampin should not be used as a single agent.

**These organisms can produce an extended beta-lactamase(ESBL)Ceftazidime resistance indicates the organism's ability to produce this enzyme.

***Pseudomonas may test as sensitive to Ceftazidime in vitro but may produce an inducible beta-lactamase in vivo.

****All Staphylococci are tested for inducible Clindamycin resistance. If inducible resistance is detected,the isolate is reported as resistant.

This Chart is for the use of PMC physicians in choosing empiric therapy prior to definitive test results.